High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant
Public ClinicalTrials.gov record NCT03128359. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Pilot Study of Post-transplant High Dose Cyclophosphamide (PTCY) as Part of Graft-Versus-Host Disease (GVHD) Prophylaxis in T-Cell Replete HLA-Mismatched Unrelated Donor (MMUD) Ablative and Reduced Intensity Hematopoietic Cell Transplantation (HCT) for Hematological Malignancies
Study identification
- NCT ID
- NCT03128359
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- City of Hope Medical Center
- Other
- Enrollment
- 38 participants
Conditions and interventions
Conditions
- Acute Leukemia
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Diffuse Large B-Cell Lymphoma
- Follicular Lymphoma
- Graft Versus Host Disease
- Hodgkin Lymphoma
- Mantle Cell Lymphoma
- Marginal Zone Lymphoma
- Myelodysplastic Syndrome
- Myeloproliferative Neoplasm
- Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Secondary Myelodysplastic Syndrome
Interventions
- Busulfan Drug
- Cyclophosphamide Drug
- Fludarabine Phosphate Drug
- Hematopoietic Cell Transplantation Procedure
- Laboratory Biomarker Analysis Other
- Melphalan Hydrochloride Drug
- Mycophenolate Mofetil Drug
- Peripheral Blood Stem Cell Transplantation Procedure
- Quality-of-Life Assessment Other
- Tacrolimus Drug
- Total-Body Irradiation Radiation
Drug · Procedure · Other + 1 more
Eligibility (public fields only)
- Age range
- 5 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 29, 2017
- Primary completion
- Jul 31, 2020
- Completion
- Sep 14, 2021
- Last update posted
- Jan 8, 2024
2017 – 2021
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope Medical Center | Duarte | California | 91010 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03128359, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 8, 2024 · Synced May 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03128359 live on ClinicalTrials.gov.